Sales Performance - The sales of pediatric lung heat cough granules increased by 50% in the first half of the year, driven by strong demand in the medical sector, especially during the winter and around the Spring Festival [3] - The sales of Ke Ke Pian, another core product, approached 50 million yuan, showing a slight decline compared to the same period last year due to tight supply of raw materials [3][5] - The company expects sales of core products to increase in the autumn and winter seasons, particularly after September, due to a rise in respiratory diseases [3][4] Product Development - In the first half of 2024, the company received production registration approvals for 7 products and passed consistency evaluations for 2 products, with 34 new products under application [4] - The company is focusing on four strategies for research and development: targeting children's health, deepening traditional Chinese medicine, expanding indications, and aligning with national policy directions [4] Future Growth Potential - The company is cultivating potential products to enrich its product line, with the compound lysine granules being a key focus for the children's health market [4] - The introduction of new packaging for the intestinal inflammation granules aims to cater to both children and adults, expanding market reach [4] - The company is leveraging the advantages of the Hainan Free Trade Port to promote export business, contributing to future growth [4][5] Raw Material Supply - In May 2023, the company acquired a 51% stake in Jiangxi Rongxing Pharmaceutical to stabilize the supply and price fluctuations of raw materials [5] - The company plans to produce more raw materials for its formulations at Jiangxi Rongxing, enhancing its upstream supply chain [5]

海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 29 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地 了解公司 2024 年半年度的经营成果、财务状况，公司计划于 2024 年 09 月 12 日下午 13:00-14:30 举行 2024 年半年度业绩说明会，就投资者关心 的问题进行交流。 一、 说明会类型 本次投资者说明会以视频录播结合网络文字互动的方式召开，公司将 证券代码：605199 证券简称：葫芦娃 公告编号：2024-054 海南葫芦娃药业集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 09 月 05 日(星期四) 至 09 月 11 日(星期三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hu luwa@huluwayaoye.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 会议召开时间：2024 年 09 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥846,714,106.03, a decrease of 7.36% compared to ¥913,979,323.00 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was ¥78,751,617.40, representing an increase of 28.33% from ¥61,364,614.89 in the previous year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,190,044.38, down 11.91% from ¥47,893,434.59 in the same period last year[15]. - The net cash flow from operating activities was -¥151,118,833.90, compared to -¥160,301,194.74 in the previous year, indicating an improvement[15]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,149,277,874.77, an increase of 2.58% from ¥1,120,385,678.79 at the end of the previous year[15]. - Total assets at the end of the reporting period were ¥3,108,986,927.32, reflecting a 1.58% increase from ¥3,060,548,675.78 at the end of the previous year[15]. - Basic and diluted earnings per share increased by 33.33% year-on-year to CNY 0.20, driven by the transfer of subsidiary equity and government subsidies[16]. - The weighted average return on equity rose by 0.97 percentage points to 6.84%[16]. - Non-recurring gains and losses totaled CNY 36,561,573.02 after tax, with significant contributions from government subsidies and asset disposals[18]. Research and Development - The company is focusing on R&D investments in children's medicine, with ongoing projects targeting infectious diseases and digestive issues[21]. - R&D investment reached 77.24 million yuan, a significant increase of 96.00% year-on-year, with ongoing progress in technological innovation[49]. - The company is actively developing new pediatric formulations, including inhalation preparations and controlled-release formulations, targeting high-end markets[45]. - The company has a strong focus on research and development, with national-level postdoctoral research stations and engineering technology research centers established[40]. - The company is advancing clinical trials for several new pediatric drugs, including the pediatric cough syrup, which has completed Phase II trials and is moving to Phase III[50]. Market and Product Development - The company currently has 53 children's drug products in production, covering a wide age range from 0 to 14 years[20]. - Seven health food products have been successfully approved for market, including various vitamin and mineral supplements[22]. - The company has established a comprehensive product matrix under four major brands to meet diverse market needs[19]. - The star product, Pediatric Lung Heat Cough and Wheezing Granules, has gained significant trust among parents and healthcare professionals[20]. - The company has launched 7 new products during the reporting period, including Ibuprofen Suspension and Cefdinir Granules, enhancing its product portfolio and supporting sustainable development[42]. Operational Efficiency - The company has implemented a production model combining "sales-driven production" and "reasonable inventory," ensuring quality management in accordance with the latest GMP standards[28]. - The newly established Meian Children's Medicine smart manufacturing plant received GMP certification during the reporting period, enhancing production efficiency and product quality through automation and intelligent management systems[28]. - The company has expanded its sales channels, including direct sales to large pharmaceutical chains and e-commerce platforms, to increase market coverage[30]. - The traditional distribution model has been gradually shifted to a distribution merchant model to comply with national policies, enhancing efficiency in delivering products to medical institutions[32]. - The company emphasizes quality in procurement, implementing strict supplier evaluations and dynamic management to ensure compliance with quality standards[27]. Environmental Responsibility - The company reported no exceedance of emission standards for volatile organic compounds, particulate matter, and other pollutants in the surrounding air[77]. - The total amount of hazardous waste generated in the first half of 2024 was 5.5771 tons for medical waste and 24.596 tons for pharmaceutical waste[79]. - The company has implemented measures to ensure that all emissions and discharges comply with national and local environmental standards[81]. - The company has established solid waste storage facilities for both general industrial solid waste and hazardous waste, all operating normally[90]. - The company is committed to reducing carbon emissions through low-nitrogen boiler modifications and energy management for electrical equipment[98]. Corporate Governance - The company has established a framework for accountability if commitments are not met, including public apologies and potential penalties[115]. - The company will ensure compliance with all legal and regulatory requirements regarding shareholding and reduction commitments[106]. - The controlling shareholder ensures that there are no direct or indirect competitive activities with subsidiaries of the company[109]. - The company has measures in place to compensate for any dilution of immediate returns, with commitments from directors and senior management linked to the execution of these measures[114]. - The company has not experienced any major changes in its integrity status during the reporting period[120]. Financial Position - Total current assets decreased to ¥1,317,783,272.17 from ¥1,442,585,174.05, a decline of approximately 8.7%[135]. - Cash and cash equivalents decreased to ¥312,916,084.83 from ¥522,689,865.24, a decrease of about 40.0%[135]. - Total liabilities increased to ¥1,919,930,370.10 from ¥1,901,175,403.43, an increase of about 1.0%[137]. - The total owner's equity at the end of the reporting period was 1,112,033,909.02, showing an increase from 1,015,265,708.78 at the end of the previous year[160]. - The company reported a total of 294,645,573.54 RMB in cash and cash equivalents at the end of the period, compared to 217,096,923.33 RMB in the previous year[148].

证券代码：605199 证券简称：葫芦娃 公告编号：2024-051 海南葫芦娃药业集团股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届董事会第四 次会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关规定，会议合 法有效。 （二）会议通知和材料于 2024 年 8 月 16 日以邮件方式发出。 （三）会议于 2024 年 8 月 28 日在海南省海口市秀英区安读一路 30 号公司会议室 以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决方式 出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体监事、高级管理人员列 席会议。 二、董事会会议审议情况 （一）审议通过了《关于公司 2024 年半年度报告及其摘要的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 芦娃药 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-049 海南葫芦娃药业集团股份有限公司 规格：3ml: 0.3g 上市许可持有人：海南葫芦娃药业集团股份有限公司 关于获得吸入用乙酰半胱氨酸溶液药品注册证书的公告 受理号：CYHS2300807 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 药品批准文号：国药准字 H20244705 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于吸入用乙酰半胱氨酸溶液的《药品注册 证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：吸入用乙酰半胱氨酸溶液 剂型：吸入制剂 注册分类：化学药品 4 类 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安全。上 述药品获得《药品注册证书》，将进一步丰富公司产品线，对公司的发展起到积极作用。 由于医药行业的特点，药品的前期研发以及产品从研制到投产的周期长、环节多，而且 药品获得证书后生产和销售也容易受到国家政策、市场环境变化等影响，药品的销售业 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605199 证券简称：葫芦娃 公告编号：2024-050 海南葫芦娃药业集团股份有限公司 关于全资子公司获得拉考沙胺口服溶液药品注册证书的公告 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所 附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、药品研发及相关 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简称"广西 维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签发的关于拉考沙 胺口服溶液的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：拉考沙胺口服溶液 剂型：口服溶液剂 注册分类：化学药品 4 类 规格：200ml：2g 上市许可持有人：广西维威制药有限公司 受理号：CYHS2301238 药品批准文号：国药准字 H20244711 拉考沙胺口服溶液由 UCB Pharma S ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-048 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海证券交易所上市审核委员会于 2024 年 8 月 26 日召开 2024 年第 21 次审议会 议，对海南葫芦娃药业集团股份有限公司（以下简称"公司"）向不特定对象发行可转换 公司债券的申请进行了审议。根据会议审议结果，公司本次向不特定对象发行可转换公 司债券的申请不符合发行条件、上市条件或信息披露要求。 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2024 年 8 月 26 日 海南葫芦娃药业集团股份有限公司 关于向不特定对象发行可转换公司债券 上海证券交易所上市审核委员会审议会议结果的公告 ...

上海证券交易所上市审核委员会 2024 年第 21 次审议会议 结果公告 海南葫芦娃药业集团股份有限公司（再融资）：不符合发行 条件、上市条件或信息披露要求。 二、上市委会议现场问询的主要问题 1.请发行人代表：（1）结合 CRO 行业市场供需、同行业可 比上市公司 2023 年预付研发款等情况，说明公司 2023 年期间预 付研发款项大幅增加的合理性。（2）结合同行业可比上市公司 2023 年预付渠道推广费、公司渠道推广费支付对象资质等情况， 说明公司 2023 年期间预付渠道推广费大幅增加的合理性。请保 荐代表人发表明确意见。 理性、真实性。请保荐代表人发表明确意见。 上海证券交易所上市审核委员会 2024 年第 21 次审议会议于 2024 年 8 月 26 日召开，现将会议审议情况公告如下： 三、需进一步落实事项 一、审议结果 2.请发行人代表结合同行业可比上市公司研发投入资本化情 况，以及公司研发投入资本化政策等，说明公司 2023 年第四季 度研发投入资本化核算是否准确，会计处理是否符合《企业会计 准则》相关规定。请保荐代表人发表明确意见。 3.请发行人代表结合报告期应收账款周转率、客户结构、20 ...

二、审议的发行人 海南葫芦娃药业集团股份有限公司（再融资） 上海证券交易所 上市审核委员会 2024 年 8 月 19 日 上海证券交易所上市审核委员会 2024 年第 21 次审议会议公告 上海证券交易所上市审核委员会定于 2024 年 8 月 26 日召开 2024 年第 21 次上市审核委员会审议会议。现将有关事项公告如 下： 一、参会上市委委员 马义涛 张朝辉 金俊超 褚冰茜 潘妙丽 ...

Market Overview - Despite a decrease in newborn numbers, the pediatric medicine industry continues to grow rapidly, driven by a large market size of approximately 250 million children aged 0-14 in China [2][3] - The Chinese pediatric medicine market faces challenges such as limited varieties and specifications, which are accelerating industry development and increasing the introduction of new products [3][4] - Government policies are increasingly supportive of pediatric medicines, with recent adjustments to the medical insurance catalog favoring traditional Chinese medicine and pediatric drugs, indicating a growth phase for this market [3][4] Sales and Distribution Models - The company's main business model is divided into three segments: direct sales, distribution, and traditional agency models [3][4] - The direct sales model connects the company directly with retail pharmacies, allowing for better market feedback and sales strategy adjustments [3][4] - The distribution model focuses on delivering products to hospitals and clinics, enhancing cooperation with medical institutions and increasing brand visibility [3][4] - The traditional agency model leverages distributors to achieve broad market coverage, catering to diverse regional and customer needs [3][4] Product Management and Strategy - The company has over 100 products on the market, with plans to launch more new products in the next 1 to 3 years, enriching its product structure [5][6] - Core products like "Pediatric Lung Heat Cough Granules" account for approximately 60% of sales in the hospital market, while also achieving nationwide coverage in the OTC market [6][7] - Future growth drivers include expanding product lines from acquired assets and developing new products with strong market potential [6][7] Market Trends and Consumer Behavior - There is a noticeable shift in consumer behavior, with parents increasingly opting for hospital visits for pediatric treatment rather than self-medication [5][6] - The pediatric medicine market is showing steady growth, particularly in the hospital sector, driven by rising demand for precision and professionalism in pediatric treatments [5][6] - The company aims to enhance product development, service quality, and brand building to solidify its position in the pediatric medicine market [5][6]